BRAF and melanoma: A study conducted by Parmenter et al. showed similar outcomes where a single treatment with a BRAF inhibitor resulted in a decrease in the OCR of melanoma cells [46], although they speculated that long-term treatments may eventually shift persister metabolism toward oxidative phosphorylation.